Cargando…

Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)

BACKGROUND: Extracorporeal blood purification has been proposed as one of the therapeutic approaches in patients with coronavirus infection, because of its beneficial impact on elimination of inflammatory cytokines. METHODS: This controlled trial has been conducted on critically ill COVID-19 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Asgharpour, Masoumeh, Mehdinezhad, Hamed, Bayani, Masoumeh, Zavareh, Mahmoud Sadeghi Haddad, Hamidi, Seyed Hossein, Akbari, Roghayeh, Ghadimi, Reza, Bijani, Ali, Mouodi, Simin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439633/
https://www.ncbi.nlm.nih.gov/pubmed/32819292
http://dx.doi.org/10.1186/s12882-020-02020-3
_version_ 1783573018080968704
author Asgharpour, Masoumeh
Mehdinezhad, Hamed
Bayani, Masoumeh
Zavareh, Mahmoud Sadeghi Haddad
Hamidi, Seyed Hossein
Akbari, Roghayeh
Ghadimi, Reza
Bijani, Ali
Mouodi, Simin
author_facet Asgharpour, Masoumeh
Mehdinezhad, Hamed
Bayani, Masoumeh
Zavareh, Mahmoud Sadeghi Haddad
Hamidi, Seyed Hossein
Akbari, Roghayeh
Ghadimi, Reza
Bijani, Ali
Mouodi, Simin
author_sort Asgharpour, Masoumeh
collection PubMed
description BACKGROUND: Extracorporeal blood purification has been proposed as one of the therapeutic approaches in patients with coronavirus infection, because of its beneficial impact on elimination of inflammatory cytokines. METHODS: This controlled trial has been conducted on critically ill COVID-19 patients admitted in the state hospital affiliated to Babol University of Medical Sciences, Iran who received different antiviral and antibacterial drugs, and different modalities of respiratory treatments and did not have positive clinical improvement. No randomization and blindness was considered. All of the participants underwent three sessions of resin-directed hemoperfusion using continuous renal replacement therapy with a mode of continuous venovenous hemofiltration (CVVH). RESULTS: Five men and five women with a mean age of 57.30 ± 18.07 years have been enrolled in the study; and six of them have improved after the intervention. Peripheral capillary oxygen saturation (SpO2) changed after each session. Mean SpO2 before the three sessions of hemoperfusion was 89.60% ± 3.94% and increased to 92.13% ± 3.28% after them (p < 0.001). Serum IL-6 showed a reduction from 139.70 ± 105.62 to 72.06 ± 65.87 pg/mL (p = 0.073); and c-reactive protein decreased from 136.25 ± 84.39 to 78.25 ± 38.67 mg/L (P = 0.016). CONCLUSIONS: Extracorporeal hemoadsorption could improve the general condition in most of recruited patients with severe coronavirus disease; however, large prospective multicenter trials in carefully selected patients are needed to definitely evaluate the efficacy of hemoperfusion in COVID-19 patients. TRIAL REGISTRATION: The research protocol has been registered in the website of Iranian Registry of Clinical Trials with the reference number IRCT20150704023055N2.
format Online
Article
Text
id pubmed-7439633
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74396332020-08-21 Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19) Asgharpour, Masoumeh Mehdinezhad, Hamed Bayani, Masoumeh Zavareh, Mahmoud Sadeghi Haddad Hamidi, Seyed Hossein Akbari, Roghayeh Ghadimi, Reza Bijani, Ali Mouodi, Simin BMC Nephrol Research Article BACKGROUND: Extracorporeal blood purification has been proposed as one of the therapeutic approaches in patients with coronavirus infection, because of its beneficial impact on elimination of inflammatory cytokines. METHODS: This controlled trial has been conducted on critically ill COVID-19 patients admitted in the state hospital affiliated to Babol University of Medical Sciences, Iran who received different antiviral and antibacterial drugs, and different modalities of respiratory treatments and did not have positive clinical improvement. No randomization and blindness was considered. All of the participants underwent three sessions of resin-directed hemoperfusion using continuous renal replacement therapy with a mode of continuous venovenous hemofiltration (CVVH). RESULTS: Five men and five women with a mean age of 57.30 ± 18.07 years have been enrolled in the study; and six of them have improved after the intervention. Peripheral capillary oxygen saturation (SpO2) changed after each session. Mean SpO2 before the three sessions of hemoperfusion was 89.60% ± 3.94% and increased to 92.13% ± 3.28% after them (p < 0.001). Serum IL-6 showed a reduction from 139.70 ± 105.62 to 72.06 ± 65.87 pg/mL (p = 0.073); and c-reactive protein decreased from 136.25 ± 84.39 to 78.25 ± 38.67 mg/L (P = 0.016). CONCLUSIONS: Extracorporeal hemoadsorption could improve the general condition in most of recruited patients with severe coronavirus disease; however, large prospective multicenter trials in carefully selected patients are needed to definitely evaluate the efficacy of hemoperfusion in COVID-19 patients. TRIAL REGISTRATION: The research protocol has been registered in the website of Iranian Registry of Clinical Trials with the reference number IRCT20150704023055N2. BioMed Central 2020-08-20 /pmc/articles/PMC7439633/ /pubmed/32819292 http://dx.doi.org/10.1186/s12882-020-02020-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Asgharpour, Masoumeh
Mehdinezhad, Hamed
Bayani, Masoumeh
Zavareh, Mahmoud Sadeghi Haddad
Hamidi, Seyed Hossein
Akbari, Roghayeh
Ghadimi, Reza
Bijani, Ali
Mouodi, Simin
Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)
title Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)
title_full Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)
title_fullStr Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)
title_full_unstemmed Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)
title_short Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)
title_sort effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (covid-19)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439633/
https://www.ncbi.nlm.nih.gov/pubmed/32819292
http://dx.doi.org/10.1186/s12882-020-02020-3
work_keys_str_mv AT asgharpourmasoumeh effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT mehdinezhadhamed effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT bayanimasoumeh effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT zavarehmahmoudsadeghihaddad effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT hamidiseyedhossein effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT akbariroghayeh effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT ghadimireza effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT bijaniali effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19
AT mouodisimin effectivenessofextracorporealbloodpurificationhemoadsorptioninpatientswithseverecoronavirusdisease2019covid19